IMU Biosciences

We're #hiring a new Data Platform Engineer in United Kingdom. Apply today or share this post with your network.

Our CSO, Adam Laing, and CBO, Jason Brown, had an engaging few days at BioEurope, connecting with many interesting groups and innovators. It was an excellent opportunity to showcase how IMU Biosciences is driving precision medicine forward across multiple diseases, through advanced immune profiling combined with our proprietary AI/ML analytics. We’re excited about the meaningful conversations and potential partnerships that emerged. #BioEurope #PrecisionMedicine #AI #Biotech #Collaboration

🎙️ What if AI could unlock the secrets of the immune system? In the latest AWS Health Innovation Podcast, AWS' Alex Merwin chats with Adam Laing, Co-founder & Chief Scientific Officer of IMU Biosciences. Discover how IMU is transforming immune profiling with AI, offering new insights into health and disease. Tune in to learn: ✨ How IMU measures 80M data points from 2,000+ immune cell subsets with just a small blood sample. 🔍 Predicting disease progression and treatment responses through deep immune profiling. 🤝 A collaborative culture that drives their success. 💡 Advances in flow cytometry that allow labeling 75 markers with unmatched precision. 🔉 https://go.aws/3YsiJIU #AWS #AWSStarups #HealthInnovation

Our Co-founder and CSO Adam Laing will be participating in the Innovation Showcase at the BioIndustry Association (BIA)’s Tech Bio UK 2024 conference on 16 October. IMU Biosciences has been selected for the showcase alongside four other innovative organisations. Each will present their achievements and vision for transforming the biotech landscape. Attendees will then have the opportunity to vote for the organisation they believe will have the most significant impact, with the winner earning a spot to present again during the final plenary session. Come and show your support for Adam and IMU Biosciences! For more information visit: https://lnkd.in/ggti5En #Conference #Biotech #Immunology

Incredible news from IMU Biosciences. The team will be collaborating on a UK-wide initiative which will help better understand how cancer patients will react to immunotherapies. The study is being led by the Francis Crick Institute and the Royal Marsden NHS trust to bring together a large network of clinical centers and academic research centers (alongside IMU!) to build a bigger picture to how individual patients will respond to immunotherapy treatment. This is such important work, when you consider only about 20% of people respond successfully to these treatments. Here’s more about this exciting new study: https://bit.ly/3Njhrd0 #medicine #innovation #AI

We are pleased to announce our participation in MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity), a new UK-wide initiative to understand immunotherapy response and side effects in cancer. IMU Biosciences will play a crucial role in this nationwide effort by analysing thousands of blood samples from patients undergoing immunotherapy using our cutting-edge technology platform. The MANIFEST consortium, led by The Francis Crick Institute and The Royal Marsden NHS Foundation Trust, has been awarded £9 million in funding from the UK government's Medical Research Council and Office for Life Sciences, with an additional £12.9 million in matched funds from industry partners. To read the full press release, visit: https://lnkd.in/dhwVCp2i #MANIFEST #Biotech #Immunology #Innovation #PrecisionMedicine #AI #ML

IMU Biosciences is delighted to announce that it has been accepted into the NVIDIA Inception Program, an initiative designed to support promising startups making advancements in AI, machine learning and data sciences. This partnership will provide IMU Biosciences with access to NVIDIA's state-of-the-art technology and expertise, further enhancing our ability to translate vast systems-level immune data into actionable insights for precision medicine. Key benefits of the programme include: • Advanced AI Optimisation: Direct support from NVIDIA's deep learning experts to enhance IMU's proprietary AI and machine learning analytics. • Specialised Training: Access to NVIDIA's cutting-edge AI training programs, deepening IMU's expertise in applying machine learning to complex immunological data. • Accelerated Computing Resources: Utilisation of NVIDIA's high-performance computing capabilities to speed up IMU's high-throughput, scalable immunophenotyping technologies. • Expanded Network: Opportunities to connect with NVIDIA's extensive network of AI-driven healthcare and biotech companies, as well as potential investors through the NVIDIA Inception VC Alliance. Read more on our website: https://lnkd.in/eFN9qYAG #NVIDIAInception #NVIDIA #Biotech #Immunology #Innovation #PrecisionMedicine #AI #ML

IMU Biosciences is delighted to announce that it has been accepted into the NVIDIA Inception Program, an initiative designed to support promising startups making advancements in AI, machine learning and data sciences. This partnership will provide IMU Biosciences with access to NVIDIA's state-of-the-art technology and expertise, further enhancing our ability to translate vast systems-level immune data into actionable insights for precision medicine. Key benefits of the programme include: • Advanced AI Optimisation: Direct support from NVIDIA's deep learning experts to enhance IMU's proprietary AI and machine learning analytics. • Specialised Training: Access to NVIDIA's cutting-edge AI training programs, deepening IMU's expertise in applying machine learning to complex immunological data. • Accelerated Computing Resources: Utilisation of NVIDIA's high-performance computing capabilities to speed up IMU's high-throughput, scalable immunophenotyping technologies. • Expanded Network: Opportunities to connect with NVIDIA's extensive network of AI-driven healthcare and biotech companies, as well as potential investors through the NVIDIA Inception VC Alliance. Read more on our website: https://lnkd.in/eFN9qYAG #NVIDIAInception #NVIDIA #Biotech #Immunology #Innovation #PrecisionMedicine #AI #ML

Our co-founders Adam Laing and Tom Hayday recently spoke to Holly Branson, Chief Purpose and Vision Officer at Virgin about IMU Biosciences’ proprietary AI powered immune profiling platform for immune profiling and its potential life-changing real-world impact. To watch the full interview, visit: https://lnkd.in/eya_2seA #Biotech #Immunology #Innovation #PrecisionMedicine #AI #ML 

We are delighted to announce the appointments of Dr. John Baker as CEO and Dr. Jason Brown as CBO. John joins IMU Biosciences from Abcam where he has been a member of the Executive team since 2016. During his time there, John led global teams spanning Business Development, R&D, Product, Marketing and most recently Supply Chain & Manufacturing. Jason joins IMU Biosciences from Evotec, where he served as Senior VP of Business Development. He brings a wealth of expertise in business development, discovery partnerships and drug discovery services. In Adam Laing’s new roles as President and CSO, he will continue to drive the Company's scientific strategy and innovation, leveraging his deep expertise in immunology and systems biology. Welcome John and Jason! To read the full press release, visit: https://lnkd.in/emGp_--3 #Appointments #Biotech #Immunology #Innovation #PrecisionMedicine #AI #ML